Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants
NCT03004768Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2017
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deucravacitinib in psoriasis, sponsored by Bristol Myers Squibb. Primary endpoints: PK exposure determined from plasma concentration versus time, Urinary/fecal Total Radioactivity recovery data and 4 more. Started Jan 2017; status: completed.
02
Drugs
deucravacitinib
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03004768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03004768.